Prepaid VAT
Value Added Tax Receivable, Noncurrent
Supplemental cash flow information:
Supplemental Cash Flow Information [Abstract]
Unrealized Gains (Losses) on Available-for-Sale Securities
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]
Convertible Debt
Convertible Debt [Member]
Leasehold improvements
Leasehold Improvements [Member]
Total research and development cost share liability
Financing Commitment, Carrying Value
Financing Commitment, Carrying Value
Fair Value Hierarchy and NAV [Domain]
Fair Value Hierarchy and NAV [Domain]
Net loss attributable to BeiGene, Ltd.
Net loss attributable to BeiGene, Ltd.
Net Income (Loss) Attributable to Parent
Purchase price, ADS (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued In Period American Depository Shares Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period American Depository Shares Exercise Price
Entity Emerging Growth Company
Entity Emerging Growth Company
Operating lease right-of-use assets
Operating Lease, Right-of-Use Asset
Short-term investments
Fair Value (Net Carrying Amount)
Debt Securities, Available-for-sale, Current
Unrecorded Unconditional Purchase Obligation [Table]
Unrecorded Unconditional Purchase Obligation [Table]
Compensation related
Employee-related Liabilities, Current
Working Capital
Working Capital [Member]
Working Capital
Rental deposits and other
Rental Deposits and Other
Amount of rental deposits and other.
Income Statement Location [Axis]
Income Statement Location [Axis]
Accumulated amortization
Finite-Lived Intangible Assets, Accumulated Amortization
Statistical Measurement [Domain]
Statistical Measurement [Domain]
Entity Address, Street Address
Entity Address, Address Line One
Entity Address, Street Address Two
Entity Address, Address Line Two
Equity securities with readily determinable fair values
Equity Securities, FV-NI, Current
Equity method investments fair value
Equity Method Investments, Fair Value Disclosure
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer [Abstract]
Entity Filer Category
Entity Filer Category
Restricted net assets
Restricted Net Assets, Amount
Restricted net assets.
Offering period (month)
Share-based Compensation Arrangement by Share-based Payment Award, Offering Period
Share-based Compensation Arrangement by Share-based Payment Award, Offering Period
Other non-current assets
Total
Other Assets, Noncurrent
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Investment, Name [Axis]
Investment, Name [Axis]
Shares available for future grants (shares)
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant
Net increase in cash, cash equivalents, and restricted cash
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Acquired Finite-Lived Intangible Assets
Acquired Finite-Lived Intangible Assets [Line Items]
Inventories
Inventories [Member]
Stand alone selling price of R&D services
Collaborative Arrangement, Stand Alone Selling Price Of Research And Development Services
Collaborative Arrangement, Stand Alone Selling Price
Ordinary shares
Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Share-based compensation
APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Number of employees (employee)
Entity Number of Employees
Licensing Agreements And Trademarks
Licensing Agreements And Trademarks [Member]
Licensing Agreements And Trademarks
Schedule of short-term investments
Debt Securities, Available-for-sale [Table Text Block]
Document Fiscal Year Focus
Document Fiscal Year Focus
Number of members (members)
Number of Members
Number of Members
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Other comprehensive (loss) income, net of tax of nil:
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]
Amortization of intangible assets
Amortization of Intangible Assets
Amortization of Intangible Assets
VIDAZA®
Vidaza [Member]
Vidaza [Member]
Schedule of inventory
Schedule of Inventory, Current [Table Text Block]
Research and development
Research and Development Expense [Member]
Fair value of intangible asset
Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure
Sale of Stock [Axis]
Sale of Stock [Axis]
Building
Building [Member]
Prepaid taxes
Prepaid Taxes
Unrealized holding (loss) gain, net
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax
Award Type [Domain]
Award Type [Domain]
Expected amortization expense
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Credit Facility [Domain]
Credit Facility [Domain]
Assets
Assets [Abstract]
Schedule of Investments
Schedule of Investments [Line Items]
Accrued Sales Rebates and Returns
Accrued Sales Rebates and Returns [Roll Forward]
Accrued Sales Rebates and Returns [Roll Forward]
Products on trial (trial)
Products On Trial
Products On Trial
Intangible Assets
Goodwill and Intangible Assets Disclosure [Text Block]
Concentration risk, percentage
Concentration Risk, Percentage
Proceeds from option exercises and employee share purchase plan
Exercise of options, ESPP and release of Restricted Share Units ("RSUs")
Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised
ESPP
Employee Share Purchase Plan2018 [Member]
The 2018 Employee Share Purchase Plan.
Number of options outstanding (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Entity Address, City
Entity Address, City or Town
Accumulated Deficit
Retained Earnings [Member]
Debt Instrument [Axis]
Debt Instrument [Axis]
Preferred stock ownership voting rights requirement threshold (percentage)
Voting Right Requirement Threshold
Voting Right Requirement Threshold
China
PRC
CHINA
Non-current liabilities:
Liabilities, Noncurrent [Abstract]
Ownership percentage (as a percent)
Noncontrolling Interest, Ownership Percentage by Parent
Commitments and Contingencies
Commitments and Contingencies Disclosure [Text Block]
China Merchants Bank
China Merchants Bank [Member]
China Merchants Bank
Related Party [Axis]
Related Party [Axis]
Accounts receivable
Increase (Decrease) in Accounts Receivable
Gain on deconsolidation of entity
Deconsolidation, Gain (Loss), Amount
Acquisitions of equipment included in accounts payable
Capital Expenditures Incurred but Not yet Paid
Exchange rate changes
Accounts Receivable, Allowance for Credit Loss, Exchange Rate Changes
Accounts Receivable, Allowance for Credit Loss, Exchange Rate Changes
Long-term bank January 22, 2020
Long Term Bank Loan Dated January 22 2020 [Member]
Long Term Bank Loan Dated January 22 2020
REVLIMID®
Revlimid [Member]
Revlimid [Member]
Junior Notes
Senior Subordinated Notes [Member]
Property, Plant and Equipment
Property, Plant and Equipment [Line Items]
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Abstract]
Comprehensive loss
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest
Deconsolidation of entity
Noncontrolling Interest, Decrease from Deconsolidation
Schedule of Segment Reporting Information, by Segment [Table]
Schedule of Segment Reporting Information, by Segment [Table]
Schedule of other long-term liabilities
Other Noncurrent Liabilities [Table Text Block]
Equity method investments, including warrants (percent)
Equity Method Investment, Ownership Percentage, Including Exercisable Warrants
Equity Method Investment, Ownership Percentage, Including Exercisable Warrants
Entity Interactive Data Current
Entity Interactive Data Current
Prepayment of property and equipment
Prepayment of Long Term Asset
Amount of prepayment of long term asset.
Repayment of short-term loan
Repayment of short-term loan
Repayments of Short-term Debt
Number of operating segments
Number of Operating Segments
Operating Expense
Operating Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Loss per share attributable to BeiGene, Ltd. (in dollars per share)
Earnings Per Share, Basic
Indefinite-lived Intangible Assets, Major Class Name [Domain]
Indefinite-lived Intangible Assets, Major Class Name [Domain]
Pension liability adjustments
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax
Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain]
Long-term Purchase Commitment, Category of Item Purchased [Domain]
Long-term Purchase Commitment, Category of Item Purchased [Domain]
Product Revenue
Revenue from Contract with Customer [Text Block]
Document Type
Document Type
Product Name [Axis]
Product Name [Axis]
Product Name [Axis]
Interest expense
Interest Expense, Debt
Schedule of net product sales
Disaggregation of Revenue [Table Text Block]
Investor
Investor [Member]
Share price, ADS (in dollars per share)
Market price, ADS (in dollars per share)
Share Price, American Depository Shares
Price of each American Depository Share. Each American Depositary Share represents 13 ordinary shares of the entity.
Entity Current Reporting Status
Entity Current Reporting Status
Pension liability
Liability, Defined Benefit Pension Plan, Noncurrent
Manufacturing equipment
Machinery and Equipment [Member]
Schedule of Investments [Table]
Schedule of Investments [Table]
Number of shares reserved and available for issuance (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized
Product Stage [Domain]
Product Stage [Domain]
Product Stage
Current period provision for expected credit losses
Accounts Receivable, Credit Loss Expense (Reversal)
Approved
Approved [Member]
Approved
Zhuhai Hillhouse (the "Related Party Loan")
Zhuhai Hillhouse Zhaohui Equity Investment Partnership [Member]
Zhuhai Hillhouse Zhaohui Equity Investment Partnership
Research and development service revenue
Collaboration Research And Development Service [Member]
Collaboration, Research and Development Service [Member]
Schedule of accrued sales rebates and returns
Schedule of Accrued Sales Rebates and Returns Current [Table Text Block]
Schedule of Accrued Sales Rebates and Returns Current [Table Text Block]
Plan Name [Axis]
Plan Name [Axis]
Short-term debt April 4, 2018
Short Term Bank Loan Dated April 4 2018 [Member]
Short Term Bank Loan Dated April 4 2018
Long-term bank November 9, 2020
Long Term Bank Loan Dated November 9 2020 [Member]
Long Term Bank Loan Dated November 9 2020
Total
Assets, Fair Value Disclosure
Long-term bank April 4, 2018
Long Term Bank Loan April42018 [Member]
Long Term Bank Loan dated April 4, 2018.
Quoted Price in Active Market for Identical Assets (Level 1)
Fair Value, Inputs, Level 1 [Member]
Number of people (person)
Number Of Persons
Number Of Persons
Investing activities:
Net Cash Provided by (Used in) Investing Activities [Abstract]
Other items, net
Other Operating Activities, Cash Flow Statement
Document Transition Report
Document Transition Report
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Abstract]
Income taxes
Income Tax Expense (Benefit), Continuing Operations [Abstract]
Finite-Lived Intangible Assets
Finite-Lived Intangible Assets [Line Items]
Total liabilities and equity
Liabilities and Equity
Prepaid research and development costs
Prepaid Research and Development Costs
Amount of consideration paid in advance for research and development that provides economic benefits within a future period of one year or the normal operating cycle, if longer.
Minimum number of biologics assets to be contributed
Number of Assets Contributed, Minimum
Minimum number of assets contributed to a joint venture.
Investments, Debt and Equity Securities [Abstract]
Investments, Debt and Equity Securities [Abstract]
Limited partner extended period (in years)
Limited Partner Extended Period
Limited Partner Extended Period
Shareholder loan
Due to Related Parties, Noncurrent
Deferred revenue, current portion
Contract with Customer, Liability, Current
Restricted cash
Restricted Cash
Additional paid-in capital
Additional Paid in Capital
Fully repaid business days (days)
Fully Repaid Business Days Period
Fully Repaid Business Days Period
Liabilities and shareholders' equity
Liabilities and Equity [Abstract]
GET
Guangzhou Get Technology Development Co Ltd [Member]
Guangzhou GET Technology Development Co., Ltd. ("GET")
Accounts payable
Increase (Decrease) in Accounts Payable
Property and equipment
Property, Plant and Equipment, Net [Abstract]
Short-term Debt, Type [Domain]
Short-term Debt, Type [Domain]
Loss Per Share
Earnings Per Share [Text Block]
Equity method investments (percent)
Equity Method Investment, Ownership Percentage
Required statutory reserve as a percentage of registered capital (as a percent)
Restricted Net Assets, Required Statutory Reserve as Percentage of Registered Capital
Required statutory reserve as a percentage of registered capital.
Cash and Cash Equivalents [Domain]
Cash and Cash Equivalents [Domain]
Prepaid expenses and other current assets
Prepaid Expense and Other Assets, Current [Abstract]
Minimum
Minimum [Member]
Income tax receivable
Income Taxes Receivable, Current
Deferred government grant income
Government Grants or Incentives Received and Deferred, Noncurrent
Government Grants or Incentives Received and Deferred, Noncurrent
Discount on purchase price of common stock (as a percent)
Share-based Compensation Arrangement by Share-based Payment Award, Discount on Purchase Price of Common Stock, Percent
Share-based Compensation Arrangement by Share-based Payment Award, Discount on Purchase Price of Common Stock, Percent
Effect of foreign exchange rate changes, net
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
Schedule of Revenues from External Customers and Long-Lived Assets [Table]
Schedule of Revenues from External Customers and Long-Lived Assets [Table]
Less: comprehensive loss attributable to noncontrolling interests
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest
Loss before income taxes
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest
Selling, general and administrative
Selling, General and Administrative Expense
Professional fees and other
Accrued Professional Fees and Other, Current
Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received and amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.
Indefinite-lived Intangible Assets [Axis]
Indefinite-lived Intangible Assets [Axis]
Accrual
Rebate and Sales Return
Rebate and Sales Return
Unrecognized tax benefits
Unrecognized Tax Benefits
Less: Rebates and sales returns
Revenue From Contract With Customer, Rebate And Sales Return
Revenue from Contract with Customer, Rebate and Sales Return
Gross Unrealized Gains
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax
Other non-current assets
Other Assets, Noncurrent [Abstract]
Number of patients (patient)
Number of Patients
Number of Patients
Trading Symbol(s)
Trading Symbol
GET Biomedical Industry Investment Fund Management Co., Ltd.
GET Biomedical Industry Investment Fund Management Co., Ltd. [Member]
GET Biomedical Industry Investment Fund Management Co., Ltd.
Deferred tax assets
Deferred Income Tax Assets, Net
Entity Address, Country
Entity Address, Country
Current liabilities:
Liabilities, Current [Abstract]
Issuance of ordinary shares in connection with collaboration
Stock Issued During Period, Value, New Issues
Long-term restricted cash
Restricted Cash and Cash Equivalents, Noncurrent
Foreign Currency Translation Adjustments
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Share-Based Compensation Expense
Share-based Payment Arrangement [Text Block]
Senior Notes
Senior Notes [Member]
Significant Unobservable Inputs (Level 3)
Fair Value, Inputs, Level 3 [Member]
Inventories
Inventory Disclosure [Text Block]
Equity securities with readily determinable fair values
Equity Securities [Member]
Issuance of ordinary shares in connection with collaboration (in shares)
Shares issued (in shares)
Stock Issued During Period, Shares, New Issues
Shareholder Loan
Shareholder Loan [Member]
Shareholder loan
Total
Reimbursement Expense
Reimbursement Expense
Ordinary shares, US$0.0001 par value per share; 9,500,000,000 shares authorized; 1,204,567,023 and 1,190,821,941 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively
Common Stock, Value, Issued
Disaggregation of Revenue
Disaggregation of Revenue [Line Items]
Purchase commitments
Long-term Purchase Commitment, Amount
Maximum percentage of eligible earnings as after-tax withholdings to purchase ordinary shares (as a percent)
Maximum Percentage of Eligible Earnings Set a Side to Purchase Ordinary Shares
Maximum Percentage of Eligible Earnings Set a Side to Purchase Ordinary Shares
Basis of presentation and consolidation
Basis of Accounting, Policy [Policy Text Block]
Commitments and contingencies
Commitments and Contingencies
Total non-current assets
Assets, Noncurrent
Total amount due to Amgen for BeiGene's portion of the development funding
Financing Commitment Expenses
Financing Commitment Expenses
Accumulated other comprehensive income
Accumulated Other Comprehensive Income (Loss), Net of Tax
Capital Addition Purchase Commitments
Capital Addition Purchase Commitments [Member]
Senior loan Reserved For JV Purchase
Senior loan Reserved For JV Purchase [Member]
Senior loan Reserved For JV Purchase
Investments Funding Commitment
Investments Funding Commitment [Member]
Investments Funding Commitment
Product Concentration Risk
Product Concentration Risk [Member]
China Construction Bank
China Construction Bank [Member]
China Construction Bank [Member]
Schedule of other non-current assets
Schedule of Other Assets, Noncurrent [Table Text Block]
Purchase of in-process research and development
Payments to Purchase In-process Research and Development
The cash outflows from the purchase of in-process research and development acquired in an exclusive license agreement.
Ownership [Axis]
Ownership [Axis]
Document Period End Date
Document Period End Date
Restricted Cash and Investments
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]
Novartis
Novartis [Member]
Novartis
Number of members required for approval (members)
Members Required For Approval
Members Required For Approval
Tislelizumab
Tislelizumab [Member]
Tislelizumab [Member]
Number of molecules (molecule)
Number Of Molecules
Number Of Molecules
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues from External Customers and Long-Lived Assets [Line Items]
Guangzhou Biologics Business
Manufacturing Facility Disclosure [Text Block]
The entire disclosure for manufacturing facility.
Total expenses
Costs and Expenses
Schedule of net product revenues by geographic area
Revenue from External Customers by Geographic Areas [Table Text Block]
Other comprehensive (loss) income before reclassifications
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax
Class of Stock [Axis]
Class of Stock [Axis]
Limited partner agreed period (in years)
Limited Partner Agreed Period
Limited Partner Agreed Period
Entity Registrant Name
Entity Registrant Name
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Interest (expense) income, net
Interest Income (Expense), Net
Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]
Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]
Work in process
Inventory, Work in Process, Net of Reserves
Prepaid expenses and other current assets
Total
Prepaid Expense and Other Assets, Current
Total transaction price, allocated
Collaborative Arrangement, Total Transaction Price, Allocated
Collaborative Arrangement, Total Transaction Price, Allocated
Financial Instrument [Axis]
Financial Instrument [Axis]
Selling, general and administrative
Selling, General and Administrative Expenses [Member]
Fair value of equity investments issued
Fair Value of Equity Investments Issued
Fair Value of Equity Investments Issued
Accrued expenses and other payables
Total
Accrued Liabilities, Current
Revenues
Product revenue – net
Revenue from Contract with Customer, Excluding Assessed Tax
Finished goods
Inventory, Finished Goods, Net of Reserves
Numerator:
Net Income (Loss) Available to Common Stockholders, Basic [Abstract]
Other
Other [Member]
Other
Payment to acquire interest in JV
Payments to Acquire Interest in Joint Venture
Number of limited partners (application)
Number of Limited Partners
Number of Limited Partners
Equity [Abstract]
Equity [Abstract]
Laboratory equipment
Laboratory Equipment [Member]
Represents information pertaining to laboratory equipment.
Fair Value Hierarchy and NAV [Axis]
Fair Value Hierarchy and NAV [Axis]
Payments
Accrued Sales Rebates and Returns, Payment
Accrued Sales Rebates and Returns, Payment
Interest receivable
Interest Receivable, Current
Ordinary Shares
Common Stock
Fair value of Leap common stock
Common Stock [Member]
Schedule of amounts and classification of reimbursement expense
Schedule Of Amounts And Classification Of Reimbursement Expense [Table Text Block]
Schedule Of Amounts And Classification Of Reimbursement Expense
Segment and Geographic Information
Segment Reporting Disclosure [Text Block]
Loss from operations
Operating Income (Loss)
Property, Plant and Equipment [Table]
Property, Plant and Equipment [Table]
Operating lease liabilities, current portion
Operating Lease, Liability, Current
Gross Unrealized Losses
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax
Description of Business, Basis of Presentation and Consolidation and Significant Accounting Policies
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]
2023
Finite-Lived Intangible Asset, Expected Amortization, Year Two
Collaborative Arrangements
Collaborative Arrangement Disclosure [Text Block]
Increase (Decrease) in Stockholders' Equity
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Abstract]
Share-based compensation expenses
Share-based Payment Arrangement, Noncash Expense
Movement in accumulated other comprehensive loss
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Additional Paid-In Capital
Additional Paid-in Capital [Member]
Cash and cash equivalents
Cash and Cash Equivalents, at Carrying Value
Depreciation expense
Depreciation
Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]
Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]
Short-term investments
Short-term Investments [Abstract]
Long-term Debt, Type [Domain]
Long-term Debt, Type [Domain]
Debt instrument accrued interest
Interest Payable
Purchases of investments
Payments to Acquire Debt Securities, Available-for-sale
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Research and development cost share liability, non-current portion
Financing Commitment, Carrying Value, Non-current
Financing Commitment, Carrying Value, Non-current
Other (expense) income, net
Other Nonoperating Income (Expense)
Other liabilities
Increase (Decrease) in Other Operating Liabilities
MapKure
MapKure [Member]
MapKure
Other investing activities
Payments for (Proceeds from) Other Investing Activities
Prepaid insurance
Prepaid Insurance
Purchases of property, plant and equipment
Payments to Acquire Property, Plant, and Equipment
Maximum
Maximum [Member]
Weighted-average ADSs outstanding - basic (in shares)
Weighted Average Number Of American Depository Shares Outstanding, Basic
Weighted Average Number of American Depository Shares Outstanding
Share-based Payment Arrangement [Abstract]
Share-based Payment Arrangement [Abstract]
Senior Loan
Senior Loan [Member]
Senior Loan
Product revenue – gross
Revenue From Contract With Customer, Excluding Assessed Tax, Gross
Revenue from Contract with Customer, Excluding Assessed Tax, Gross
Fair value of financing commitment
Fair Value Of Financing Commitment
Fair Value Of Financing Commitment
Total liabilities
Liabilities
Shares cancelled or forfeited (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Cancelled or Forfeited in Period
The number of shares under options granted in a plan that were canceled after the initial public offering date, as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.
Raw materials
Inventory, Raw Materials, Net of Reserves
Legal Entity [Axis]
Legal Entity [Axis]
Award Type [Axis]
Award Type [Axis]
2022
Finite-Lived Intangible Asset, Expected Amortization, Year One
Financing activities:
Net Cash Provided by (Used in) Financing Activities [Abstract]
Total equity
Stockholders' Equity Attributable to Parent
2011 Plan
Share Incentive Plan2011 [Member]
2011 Share Incentive Plan.
Product candidate (candidate)
Product Candidate
Product Candidate
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Related Disclosures [Abstract]
Ordinary shares, shares issued (in shares)
Common Stock, Shares, Issued
Schedule of fair value of the common stock and warrants
Debt Securities, Trading, and Equity Securities, FV-NI [Table Text Block]
2018 Plan
Inducement Equity Plan2018 [Member]
The 2018 Inducement Equity Plan.
Short-term restricted cash
Short-term restricted cash
Restricted Cash and Cash Equivalents, Current
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Abstract]
Interest capitalized
Interest Costs Capitalized
Restricted Net Assets Disclosure [Abstract]
Restricted Net Assets Disclosure [Abstract]
Restricted Net Assets Disclosure [Abstract]
Equity:
Stockholders' Equity Attributable to Parent [Abstract]
Schedule of accumulated other comprehensive income
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]
Supplemental non-cash information:
Noncash Investing and Financing Items [Abstract]
Software, electronics and office equipment
Software and Software Development Costs [Member]
Accumulated Other Comprehensive Income
Comprehensive Income (Loss) Note [Text Block]
Operating lease liabilities, non-current portion
Operating Lease, Liability, Noncurrent
Measurement Frequency [Domain]
Measurement Frequency [Domain]
Upfront cash payment received
Collaborative Arrangement, Upfront Cash Payment Received
Collaborative Arrangement, Upfront Cash Payment Received
Face amount
Debt Instrument, Face Amount
Trading license
Licensing Agreements [Member]
Proceeds from short-term loans
Proceeds from Short-term Debt
Proceeds from ADS shares
Proceeds from Issuance of Asset Depository Shares
Proceeds from Issuance of Asset Depository Shares
City Area Code
City Area Code
Market price (in dollars per share)
Share Price
Collaboration revenue
Collaboration
Collaboration [Member]
Collaboration [Member]
Accumulated deficit
Retained Earnings (Accumulated Deficit)
Schedule of prepaid expenses and other current assets
Schedule of Prepaid Expenses and Other Current Assets [Table Text Block]
Tabular disclosure of prepaid expenses and other current assets.
Extension Period (month)
Debt Instrument Extension Period
Debt Instrument Extension Period
Restricted Share Units (RSUs)
Restricted Stock Units (RSUs) [Member]
Statement of Stockholders' Equity [Abstract]
Statement of Stockholders' Equity [Abstract]
Fair value of cost share liability
Fair Value Of Liability Acquired
Fair Value Of Liability Acquired
Exercise of options, ESPP and release of RSUs (in shares)
Number of ordinary shares issued ( in shares)
Stock Issued During Period, Shares, Employee Stock Purchase Plans
Equity method investment
Equity Method Investments
U.S. treasury securities
US Treasury Securities [Member]
Income Statement [Abstract]
Income Statement [Abstract]
Amendment Flag
Amendment Flag
Inventory Disclosure [Abstract]
Inventory Disclosure [Abstract]
Summary of shares issued under employee share purchase plan
Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]
Number of countries which entity operates (country)
Number of Countries in which Entity Operates
XGEVA®
Xgeva [Member]
Xgeva
Finite-Lived Intangible Assets by Major Class [Axis]
Finite-Lived Intangible Assets by Major Class [Axis]
Balance at the beginning of period
Balance at the end of period
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
Income tax (benefit) expense
Income Tax Expense (Benefit)
Other Commitments [Domain]
Other Commitments [Domain]
Accounts receivable, net
Accounts Receivable, after Allowance for Credit Loss, Current
Equity Components [Axis]
Equity Components [Axis]
Weighted-average ADSs outstanding - diluted (in shares)
Weighted Average Number Of American Depository Shares Outstanding, Diluted
Weighted Average Number Of American Depository Shares Outstanding, Diluted
Accumulated Other Comprehensive Income (Loss) [Table]
Accumulated Other Comprehensive Income (Loss) [Table]
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Abstract]
Total current assets
Assets, Current
Accrued expenses and other payables
Accounts Payable and Accrued Liabilities, Current [Abstract]
Concentration Risk Type [Domain]
Concentration Risk Type [Domain]
Disaggregation of Revenue [Table]
Disaggregation of Revenue [Table]
Sale of Stock [Domain]
Sale of Stock [Domain]
Denominator:
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Inventories
Total inventories
Inventory, Net
Approved Medicines
Approved Medicines [Member]
Approved Medicines
Entity File Number
Entity File Number
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments and Joint Ventures [Abstract]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Statement of Financial Position [Abstract]
Statement of Financial Position [Abstract]
Investment fund
Equity Method Investment, Aggregate Cost
Short-term debt
Long-term Debt, Current Maturities
Product and Service [Axis]
Product and Service [Axis]
Share-based compensation
Share-based Payment Arrangement, Additional Disclosure [Abstract]
Property, Plant and Equipment, Type [Domain]
Long-Lived Tangible Asset [Domain]
Research and development cost share liability, current portion
Research And Development Cost Share Liability, Current Portion
Research And Development Cost Share Liability, Current Portion
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Prepaid manufacturing cost
Prepaid Manufacturing Costs
Prepaid Manufacturing Costs
Accounts Receivable, Allowance for Credit Loss
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Entity Small Business
Entity Small Business
Equity securities without readily determinable fair values
Equity Securities without Readily Determinable Fair Value, Amount
Product revenue
Revenue Benchmark [Member]
BRUKINSA®
Brukinsa [Member]
Brukinsa [Member]
Equity Component [Domain]
Equity Component [Domain]
Foreign currency translation adjustments
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax
Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]
Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]
Schedule of Equity Method Investments [Table]
Schedule of Equity Method Investments [Table]
Net product revenues by geographic area
Geographic Areas, Revenues from External Customers [Abstract]
Pamiparib
Pamiparib [Member]
Pamiparib
Statement [Line Items]
Statement [Line Items]
Products in commercial or clinical stage (product)
Products in Commercial Or Clinical Development
Products in Commercial Or Clinical Development
Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]
Category of Item Purchased [Axis]
Category of Item Purchased [Axis]
Deferred revenue
Increase (Decrease) in Contract with Customer, Liability
Product Stage [Axis]
Product Stage [Axis]
Product Stage
Purchases of investments
Payments to Acquire Investments
Remaining portion of development funding cap
Other commitments
Other Commitment
Short-term Debt, Type [Axis]
Short-term Debt, Type [Axis]
Series B preferred stock
Series B Preferred Stock [Member]
Counterparty Name [Domain]
Counterparty Name [Domain]
Beijing Innerway Bio-tech Co., Ltd
Beijing Innerway Bio-tech Co., Ltd [Member]
Beijing Innerway Bio-tech Co., Ltd [Member]
Debt Disclosure [Abstract]
Debt Disclosure [Abstract]
JV Share Repurchase
JV Share Repurchase [Member]
JV Share Repurchase
Significant Other Observable Inputs (Level 2)
Fair Value, Inputs, Level 2 [Member]
Property, Plant and Equipment, Type [Axis]
Long-Lived Tangible Asset [Axis]
Minimum Purchase Commitments For Supply Purchased
Minimum Purchase Commitments For Supply Purchased [Member]
Minimum Purchase Commitments For Supply Purchased [Member]
Subsidiary, Sale of Stock
Subsidiary, Sale of Stock [Line Items]
Deferred revenue, non-current portion
Contract with Customer, Liability, Noncurrent
Segment Reporting [Abstract]
Segment Reporting [Abstract]
Entity [Domain]
Entity [Domain]
Amortized Cost
Debt Securities, Available-for-sale, Amortized Cost
Useful life (in years)
Finite-Lived Intangible Asset, Useful Life
Loss per American Depositary Share ("ADS") (in dollars per share)
Earnings Per American Depository Share, Per Share
Earnings Per American Depository Share, Per Share
Use of estimates
Use of Estimates, Policy [Policy Text Block]
Granted (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Schedule of the computations of basic and diluted earnings (loss) per share
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
Entity Shell Company
Entity Shell Company
Local Phone Number
Local Phone Number
Summary of total compensation cost recognized
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
China Industrial Bank
China Industrial Bank [Member]
China Industrial Bank [Member]
Prepayment of facility capacity expansion activities
Prepaid Construction Cost
Prepaid Construction Cost
Proceeds from sale of ordinary shares, net of cost
Payments to acquire equity interest
Proceeds from Issuance of Common Stock
Total assets
Assets
Investments [Domain]
Investment, Name [Domain]
Deferred income tax benefits
Deferred Income Taxes and Tax Credits
Plan Name [Domain]
Plan Name [Domain]
Ordinary shares, shares authorized (in shares)
Common Stock, Shares Authorized
Interest paid
Interest Paid, Excluding Capitalized Interest, Operating Activities
Geographical [Domain]
Geographical [Domain]
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
Net Income (Loss) Attributable to Parent [Abstract]
Share-based compensation
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Noncontrolling Interests
Noncontrolling Interest [Member]
Research and development
Research and development expense
Research and Development Expense
Product and Service [Domain]
Product and Service [Domain]
Amgen, Inc
Amgen, Inc
Amgen, Inc [Member]
Amgen, Inc [Member]
Supplemental Balance Sheet Information
Supplemental Balance Sheet Disclosures [Text Block]
Research and development cost share liability, non-current portion
Research And Development Cost Share Liability, Non-current Portion
Research And Development Cost Share Liability, Non-current Portion
Fixed annual interest rate (as a percent)
Debt Instrument, Interest Rate, Stated Percentage
Less: net loss attributable to noncontrolling interests
Less: Net loss attributable to noncontrolling interest
Net Income (Loss) Attributable to Noncontrolling Interest
Total non-current liabilities
Liabilities, Noncurrent
Share-based Compensation Arrangement by Share-based Payment Award
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Commercial activities
Accrued Expenses, Commercial Activities
Accrued Expenses, Commercial Activities
Measurement Frequency [Axis]
Measurement Frequency [Axis]
Net cash used in operating activities
Net Cash Provided by (Used in) Operating Activities
Segment information
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Summary of short-term and long-term debt obligations
Schedule of Debt [Table Text Block]
Fair Value, Recurring and Nonrecurring [Table]
Fair Value, Recurring and Nonrecurring [Table]
Acquired in-process research and development
Research and Development in Process
Schedule of Long-term Debt Instruments [Table]
Schedule of Long-term Debt Instruments [Table]
Entity Tax Identification Number
Entity Tax Identification Number
Non-trade receivable
Other Receivables, Net, Current
Geographical [Axis]
Geographical [Axis]
Assets at fair value on a recurring basis
Fair Value, Net Asset (Liability) [Abstract]
Extension options (option)
Debt Instrument Extension Options
Debt Instrument Extension Options
Weighted average shares outstanding—basic (in shares)
Weighted Average Number of Shares Outstanding, Basic
Per share acquisition price (in dollars per share)
Sale of Stock, Price Per Share
Leap Therapeutic, Inc
Leap Therapeutic, Inc [Member]
Leap Therapeutic, Inc [Member]
Product revenue, net
Product
Product [Member]
Income taxes paid
Income Taxes Paid, Net
Comprehensive loss attributable to BeiGene, Ltd.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Net cash provided by financing activities
Net Cash Provided by (Used in) Financing Activities
Product Name [Domain]
Product Name [Domain]
[Domain] for Product Name [Axis]
Deferred tax liabilities
Deferred Income Tax Liabilities, Net
Loans Payable
Loans Payable [Member]
Unrealized losses/(gains) on equity investments
Gains (losses) from equity investments
Income (Loss) from Equity Method Investments
Fair Value Measurements
Fair Value Disclosures [Text Block]
Product distribution rights
Distribution Rights [Member]
Accounts payable
Accounts Payable, Current
Concentration Risk Type [Axis]
Concentration Risk Type [Axis]
Short-term debt January 22 2020
Short Term Bank Loan Dated January 22 2020 [Member]
Short Term Bank Loan Dated January 22 2020
Total
Parent [Member]
Depreciation and amortization expense
Depreciation, Depletion and Amortization
2024
Finite-Lived Intangible Asset, Expected Amortization, Year Three
China Minsheng Bank (the "Senior Loan")
China Minsheng Bank [Member]
China Minsheng Bank
Summary of assets and liabilities measured at fair value on a recurring basis
Fair Value, Assets Measured on Recurring Basis [Table Text Block]
Proceeds from long-term loan
Proceeds from Long-term Lines of Credit
Accumulated Other Comprehensive Income
AOCI Attributable to Parent [Member]
Remainder of 2021
Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
Inventories
Increase (Decrease) in Inventories
Research and development cost share liability, current portion
Financing Commitment, Carrying Value, Current
Financing Commitment, Carrying Value, Current
Schedule of collaboration agreements
Collaboration Agreements [Table Text Block]
Collaboration Agreements [Table Text Block]
Collaborative Arrangement, Accounts Payable On Inventory Purchases
Collaborative Arrangement, Accounts Payable On Inventory Purchases
Collaborative Arrangement, Accounts Payable On Inventory Purchases
Research and Development Arrangement
Research and Development Arrangement [Member]
Ordinary shares, shares outstanding (in shares)
Balance at the beginning of period (in shares)
Balance at the ending of period (in shares)
Common Stock, Shares, Outstanding
Long-term investments (Note 4)
Long-term Investments
Financial Instruments [Domain]
Financial Instruments [Domain]
Ownership percentage immediately after transaction (as a percent)
Sale of Stock, Percentage of Ownership after Transaction
Limited partner investment period (in years)
Limited Partner Investment Period
Limited Partner Investment Period
Cost of sales - product
Cost of Goods and Services Sold
Revenues
Revenues [Abstract]
Other
Other Sundry Liabilities, Noncurrent
Beigene
Beigene Ltd [Member]
Beigene Ltd [Member]
Working Capital Facility
Working Capital Facility [Member]
Working Capital Facility
Concentration Risk Benchmark [Domain]
Concentration Risk Benchmark [Domain]
Line of Credit Facility, Lender [Domain]
Line of Credit Facility, Lender [Domain]
Research and Development [Abstract]
Research and Development [Abstract]
Sales rebates and returns related
Balance at beginning of the period
Balance at end of the period
Accrued Sales Rebates and Returns, Current
Accrued Sales Rebates and Returns, Current
Schedule of components of property, plant and equipment
Property, Plant and Equipment [Table Text Block]
Term (in years)
Debt instrument term (in years)
Debt Instrument, Term
Income Statement Location [Domain]
Income Statement Location [Domain]
Increase in ordinary shares authorized (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized
SpringWorks
SpringWorks [Member]
SpringWorks
Property, plant and equipment, net
Property, plant and equipment, net
Property, Plant and Equipment, Net
Other
Other Prepaid Expense, Current
Property, plant and equipment
Property, Plant and Equipment Disclosure [Text Block]
Other long-term liabilities
Total
Other Liabilities, Noncurrent
Benefit plan obligation
Defined Benefit Plan, Benefit Obligation
Acquired in-process research and development included in accrued expenses
Acquired In Process Research And Development But Not Yet Paid
Acquired In Process Research And Development But Not Yet Paid
Cash capital contribution, agreed amount
Agreed Contribution Amount to Acquire Interest in Joint Venture
Amount agreed as contribution to a joint venture.
Lender Name [Axis]
Lender Name [Axis]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Repayment of long-term loan
Repayments of Long-term Debt
Debt Instrument
Debt Instrument [Line Items]
Earnings Per Share [Abstract]
Collaborative Arrangement
Collaborative Arrangement [Member]
Proceeds from research and development cost share liability
Proceeds From Research And Development Financing Liability
Proceeds From Research And Development Financing Liability
Junior Loan General Corporate Use
Junior Loan General Corporate Use [Member]
Junior Loan General Corporate Use
Property, plant and equipment, at cost
Property, Plant and Equipment, Gross
Balance at beginning of the period
Balance at end of the period
Accounts Receivable, Allowance for Credit Loss
Document Quarterly Report
Document Quarterly Report
Other assets
Increase (Decrease) in Other Operating Assets
Amounts reclassified from accumulated other comprehensive income
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax
Proceeds from sale or maturity of investments
Proceeds from Sale of Debt Securities, Available-for-sale
BeiGene (Hong Kong) Co., Limited.(“BeiGene HK”)
Beigene Hong Kong Co Limited [Member]
BeiGene (Hong Kong) Co., Limited
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Pension Commitment
Pension Commitment [Member]
Pension Commitment
Maximum proceeds from milestones
Collaborative Arrangement, Maximum Achievement Of Regulatory Milestones
Collaborative Arrangement, Maximum Achievement Of Regulatory Milestones
Expenses
Costs and Expenses [Abstract]
Clinical Development
Clinical Development [Member]
Clinical Development
Maximum commitment
Long-term Funding Commitment, Maximum Amount
Long-term Funding Commitment, Maximum Amount
Long-term bank loans
Long-term Debt, Excluding Current Maturities
Compensation expense
Share-based Payment Arrangement, Expense
Schedule of Equity Method Investments [Line Items]
Schedule of Equity Method Investments [Line Items]
Accrued expenses and other payables
Increase (Decrease) in Other Accounts Payable and Accrued Liabilities
Minority interest in investment (as a percent)
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners
Document Fiscal Period Focus
Document Fiscal Period Focus
Series A preferred stock
Series A Preferred Stock [Member]
Net loss
Net loss
Net income (loss)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
BeiGene Biologics Co., Ltd. (BeiGene Biologics)
Beigene Biologics Co Ltd [Member]
BeiGene Biologics Co., Ltd. (“BeiGene Biologics”)
Unrecorded Unconditional Purchase Obligation [Line Items]
Unrecorded Unconditional Purchase Obligation [Line Items]
Counterparty Name [Axis]
Counterparty Name [Axis]
Share options
Employee And Nonemployee Stock Option [Member]
An arrangement whereby an employee or non-employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.
Construction in progress
Construction in Progress [Member]
Cash, cash equivalents, and restricted cash at beginning of period
Cash, cash equivalents, and restricted cash at end of period
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
BeiGene (Guangzhou) Co., Ltd. (“BeiGene Guangzhou”)
Beigene Guangzhou Co Ltd [Member]
BeiGene (Guangzhou) Co., Ltd.
Acquisition Facility
Acquisition Facility [Member]
Acquisition Facility
United States
UNITED STATES
Sale of stock shares received (in shares)
Sale of Stock, Number of Shares Issued in Transaction
Ordinary shares, par value (in dollars per share)
Common Stock, Par or Stated Value Per Share
Allowance for credit loss
Debt Securities, Available-for-sale, Allowance for Credit Loss
Shares owned (in shares)
Investment Owned, Balance, Shares
Schedule of accrued expenses and other payables
Accrued Liabilities, Accounts Payable, Other, and Other Liabilities, Current [Table Text Block]
Tabular disclosure of accrued liabilities, other accounts payable, and other liabilities, current.
Statement of Comprehensive Income [Abstract]
Statement of Comprehensive Income [Abstract]
Tax payable
Taxes Payable, Current
Current assets:
Assets, Current [Abstract]
Research and Development Arrangement, Contract to Perform for Others
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Gross carrying amount
Finite-Lived Intangible Assets, Gross
Finite-lived intangible assets:
Other intangible assets
Finite-Lived Intangible Assets, Net [Abstract]
Entity Central Index Key
Entity Central Index Key
Schedule of intangible assets outstanding and amortization expense
Schedule of Finite-Lived Intangible Assets [Table Text Block]
Name of each exchange on which registered
Security Exchange Name
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Maximum achievement of sales milestone
Collaborative Arrangement, Maximum Achievement Of Sales Milestone
Collaborative Arrangement, Maximum Achievement Of Sales Milestone
Cash equivalents
Cash and Cash Equivalents, Fair Value Disclosure
Restricted Net Assets
Restricted Assets Disclosure [Text Block]
Purchase and Capital commitments
Unconditional Purchase Obligations (Excluding Capital Stock Redemptions) [Abstract]
Use of shares reserved for share option exercises (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
ABRAXANE®
Abraxane [Member]
Abraxane [Member]
Weighted average shares outstanding - diluted (in shares)
Weighted Average Number of Shares Outstanding, Diluted
Related Party Loan
Related Party Loan [Member]
Related Party Loan
Other comprehensive income (loss)
Net-current period other comprehensive (loss) income
Other Comprehensive Income (Loss), Net of Tax
Recurring basis
Fair Value, Recurring [Member]
Income Taxes
Income Tax Disclosure [Text Block]
Related Party [Domain]
Related Party [Domain]
Long-term Debt, Type [Axis]
Long-term Debt, Type [Axis]
Current Fiscal Year End Date
Current Fiscal Year End Date
Limited partner projected payback period (in years)
Limited Partner Projected Payback Period
Limited Partner Projected Payback Period
Shareholders’ Equity
Stockholders' Equity Note Disclosure [Text Block]
Amounts written-off
Accounts Receivable, Allowance for Credit Loss, Writeoff
Short-term debt September 24, 2020
Short Term Bank Loan Dated September 24 2020 [Member]
Short Term Bank Loan Dated September 24 2020
Other long-term liabilities
Other Liabilities, Noncurrent [Abstract]
External research and development activities related
Accrued Liabilities, External Research And Development
Carrying value as of the balance sheet date of the obligations incurred through that date related to external research and development activities related
Two Individuals
Two Individuals [Member]
Two Individuals
Statement of Cash Flows [Abstract]
Statement of Cash Flows [Abstract]
2025 and thereafter
Finite-Lived Intangible Asset, Expected Amortization, After Year Three
Finite-Lived Intangible Asset, Expected Amortization, After Year Three
Finite-Lived Intangible Assets, Major Class Name [Domain]
Finite-Lived Intangible Assets, Major Class Name [Domain]
Credit Facility [Axis]
Credit Facility [Axis]
Net cash provided by (used in) investing activities
Net Cash Provided by (Used in) Investing Activities
Changes in operating assets and liabilities:
Increase (Decrease) in Operating Capital [Abstract]
Less accumulated depreciation
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Amortization of research and development cost share liability
Amortization Of Financing Commitment
Amortization Of Financing Commitment
Operating activities:
Net Cash Provided by (Used in) Operating Activities [Abstract]
Interest Rate
Debt Instrument, Interest Rate During Period
Selling, general and administrative
General and Administrative Expense [Member]
Payroll tax receivable
Payroll Tax Receivable, Current
Payroll Tax Receivable, Current
Total current liabilities
Liabilities, Current
Class of Stock [Domain]
Class of Stock [Domain]
Minimum required statutory reserve of annual after-tax profit (as a percent)
Restricted Net Assets, Minimum Required Statutory Reserve of Annual After-tax Profit, Percentage
Minimum required statutory reserve of annual after-tax profit as a percentage.
Increase in uncertain tax position
Unrecognized Tax Benefits, Increase Resulting from Tax Credit and Incentives
Unrecognized Tax Benefits, Increase Resulting from tax credit and incentives.
Maximum borrowing capacity
Line of Credit Facility, Maximum Borrowing Capacity
Money market funds
Money Market Funds [Member]
Segment Reporting Information
Segment Reporting Information [Line Items]
Ownership [Domain]
Ownership [Domain]
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Planned clinical trial (trial)
Planned Clinical Trials
Planned Clinical Trials
Purchase price, ordinary (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued In Period Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period Exercise Price
Debt Instrument, Name [Domain]
Debt Instrument, Name [Domain]
Title of each class
Title of 12(b) Security
Warrants and Rights Subject to Mandatory Redemption
Fair value of Leap warrants
Warrants and Rights Subject to Mandatory Redemption [Member]
Statement [Table]
Statement [Table]
Recent accounting pronouncements
New Accounting Pronouncements, Policy [Policy Text Block]
Other Commitments [Axis]
Other Commitments [Axis]
Statistical Measurement [Axis]
Statistical Measurement [Axis]
Number of general partner (application)
Number Of General Partner
Number Of General Partner
Cover [Abstract]
Cover [Abstract]
Organization
Shareholders' equity
Stockholders' Equity Note [Abstract]
Goodwill
Goodwill
Intangible assets, net
Intangible assets, net
Finite-Lived Intangible Assets, Net
Noncontrolling interest
Stockholders' Equity Attributable to Noncontrolling Interest
Commercialization term (years)
Commercialization Term
Commercialization Term
CIP
Construction in Progress, Gross
Cost of sales - product
Cost of Sales [Member]
Employee tax withholdings
Accrued Income Taxes, Current
License revenue
License [Member]
Amortization of research and development cost share liability
Amortization Of Research And Development Financing Liability
Amortization Of Research And Development Financing Liability
Other
All Other Countries Except China And United States Of America [Member]
All Other Countries Except China and The United States of America [Member]
2016 Plan
Share Option And Incentive Plan2016 [Member]
The 2016 Share Option and Incentive Plan.
Developed product
Developed Technology Rights [Member]
Cash and Cash Equivalents [Axis]
Cash and Cash Equivalents [Axis]
Concentration Risk Benchmark [Axis]
Concentration Risk Benchmark [Axis]
Pension Liability Adjustments
Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]
Allowance for credit loss rollforward
Accounts Receivable, Allowance for Credit Loss [Table Text Block]
Schedule of Finite-Lived Intangible Assets [Table]
Schedule of Finite-Lived Intangible Assets [Table]
Debt
Long-term Debt [Text Block]
Adjustments to reconcile net loss to net cash used in operating activities:
Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Proceeds
Proceeds, Employee Share Purchase Plan
Proceeds, Employee Share Purchase Plan